Zymeworks Inc.
ZYMENasdaq
$24.19
0.0%Jul 17 close · end-of-day
Price
1Y↑ +78.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.8B
Enterprise Value
$1.6B
P/E
—
P/S
22.2
P/B
11.0
EV/EBITDA
—
PEG
—
FCF Yield
-4.3%
Dividend Yield
—
Revenue (TTM)
$81.3M
Net Income (TTM)
-$102.7M
Free Cash Flow (TTM)
-$77.0M
Gross Margin
—
Operating Margin
-140.3%
Net Margin
-126.3%
ROE
-62.7%
ROIC
—
Debt / Equity
—
Net Cash
$244.3M
Return 1Y
+67.1%
Company profile
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
- CEO
- Kenneth H. Galbraith
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 460
- Headquarters
- Delaware
- Website
- zymeworks.com
Earnings
ZYME Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.4M↓ -91.1%
Diluted EPS-$0.59↑ +96.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $39.0M | $26.7M | $412.5M | $76.0M | $76.3M | $106.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$187.5M | -$215.6M | $130.5M | -$138.1M | -$137.1M | -$92.5M |
| Net income | -$180.6M | -$211.8M | $124.3M | -$118.7M | -$122.7M | -$81.1M |
| Diluted EPS | -$3.58 | -$4.61 | $1.90 | -$1.72 | -$1.62 | -$1.08 |
| Operating cash flow | -$151.4M | -$192.5M | $144.1M | -$118.3M | -$110.1M | -$33.0M |
| Free cash flow | -$155.7M | -$204.9M | $136.0M | -$120.8M | -$112.0M | -$34.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -481.3% | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Net margin | -463.5% | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.2M | $16.0M | $31.0M | $27.1M | $48.7M | $27.6M | $2.5M | $2.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$42.9M | -$34.2M | -$22.2M | -$25.6M | -$674,000.00 | -$22.1M | -$44.2M | -$47.1M |
| Net income | -$37.7M | -$29.9M | -$23.5M | -$22.6M | $2.3M | -$19.6M | -$41.2M | -$44.2M |
| Diluted EPS | -$0.49 | -$0.39 | -$0.32 | -$0.30 | $0.03 | -$0.26 | -$0.55 | -$0.59 |
| Operating cash flow | -$25.0M | -$5.9M | -$41.5M | -$3.4M | $12.1M | -$31.4M | -$10.3M | -$45.7M |
| Free cash flow | -$25.6M | -$6.8M | -$41.8M | -$3.4M | $11.6M | -$31.8M | -$10.8M | -$45.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -222.9% | -213.8% | -71.6% | -94.5% | -1.4% | -80.1% | -1755.5% | -1956.7% |
| Net margin | -195.8% | -186.6% | -75.8% | -83.5% | 4.8% | -71.0% | -1638.5% | -1834.0% |
Company news
Jul 16, 2026
Jul 1, 2026
Jun 30, 2026
Jun 29, 2026
- 21d agoSector Update: Healthcare Stocks Higher Late Afternoonfinance.yahoo.com
- 21d agoZymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholdersstocktwits.com
- 21d agoZymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.finance.yahoo.com
- 21d agoWhy This Biotech Stock Is Falling After a $929 Million Buyout Lifelinefinance.yahoo.com
- 21d agoZymeworks to Acquire Theravance Biopharma in $929 Million Dealfinance.yahoo.com
- 21d agoZymeworks to Acquire Theravance Biopharma, Inc.finance.yahoo.com
- 21d agoTHERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHTfinance.yahoo.com
- 21d agoTheravance, after clinical setbacks, agrees to $929M buyoutbiopharmadive.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.